In other fields, such as HIV or oncology, joint modeling has been extensively used to, for example, assess survival-adjusted CD4 counts or to model longitudinal tumor volume and tumor-related mortality.10,14,19,20 For ALS clinical trials specifically, joint models are relatively uncommon and have previously only been applied to adjust for informative censoring in longitudinal ALSFRS-R patterns.1,15 In the study by Healy and Schoenfeld,1 the joint model is compared with the CAFS for various treatment scenarios. This evidence concerns the gene CD4 and amyotrophic lateral sclerosis.